openPR Logo
Press release

Nanion increases throughput and cuts costs with a new industrial 96-channel patch clamp screening robot

11-19-2008 03:22 PM CET | Science & Education

Press release from: Nanion Technologies

Nanion increases throughput and cuts costs with a new industrial

Munich, Germany, November 18th, 2008; Today, Nanion announces the late-stage development of a new automated patch clamp platform: the SyncroPatch 96. Developed to meet the throughput demands of industrial ion channel drug screening and safety profiling, and with a price-per-data-point compatible with screening standards, the SyncroPatch 96 will offer the highest throughput in the market for high quality HTS-oriented ion channel screening.

Following the successful market introduction of two automated patch clamp devices, the Port-a-Patch (2004) and the Patchliner (2006), Nanion now introduces the SyncroPatch 96. Nanion's Patchliner and Port-a-Patch platforms enjoy great popularity in both academic and industrial settings and have received enthusiastic user feedback in customer surveys such as the HTStec report. Building on their success, the new SyncroPatch 96 vastly increases throughput while reducing the cost per data point to a level compatible with industrial ion channel screening requirements.

“There is a gap between the demands in ion channel drug screening and the capability of the high quality automated patch clamp platforms currently available on the market. Pharmaceutical companies want higher throughput and lower cost per data point, whilst maintaining data quality. The SyncroPatch96 will fill this gap, by providing high throughput, high quality patch clamp recordings, at a low enough cost to keep screeners happy.” says Dr. Niels Fertig, CEO of Nanion.
The SyncroPatch 96 acquires simultaneous recordings from 96 individual cells in a well-plate format and allows for screening of both ligand- and voltage-gated ion channels. The platform supports giga-seal recordings, continuous recording during compound application and addition of multiple compounds to each of the 96 cells. The SyncroPatch 96 will be launched in 2009.

Nanion Technologies GmbH is a German Private Limited Company and was founded in 2002 as a spin-off from the Center for Nanoscience (CeNS) of the University of Munich. Nanion’s team has developed and globally established two highly successful automated patch clamp instruments as enabling tools for sophisticated and high throughput applications for ion channel research and drug discovery.
Nanion's instruments use planar patch clamp chips which replace the traditional glass pipette used in the technique of patch clamping. Nanion was nominated in 2007 for Germany's most prestigious innovation award the Deutscher Zukunftspreis (German Future Prize, Federal President's Award for Technology and Innovation).

Nanion Technologies GmbH
Erzgiessereistrasse 4
80335 Munich
Germany
Phone: +49 89 218997972; Fax: +49 89 218997972, email: info@nanion.de
www.nanion.de

Press contact: Dr. Cecilia Farre, email: info@nanion.de, Phone: +49 89 218997973

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Nanion increases throughput and cuts costs with a new industrial 96-channel patch clamp screening robot here

News-ID: 59976 • Views: 868

More Releases from Nanion Technologies

Nanion Starts Shipping the SyncroPatch 384 Patch Engine - a Revolutionary Instru …
The brand-new SyncroPatch 384 Patch Engine (PE) now released by Nanion Technologies propels ion channel drug discovery to a new level. Designed for seamless integration into process-automated drug screening environments, the Patch Engine is equipped with 384 patch clamp amplifiers and an advanced 384 channel liquid handling robot. The SyncroPatch 384PE is the high quality, automated patch clamp system able to finally thrust gold standard electrophysiology from secondary to primary
Nanion Introduces New Product Family: CardioExcyte 96 for Cardiac Toxicity Profi …
Munich, Germany, September 12, 2013; The CardioExcyte 96 is a high resolution device recording contractility in intact cardiomyocyte networks utilizing non-invasive impedance measurements. The system allows cost-efficient, early compound safety profiling using stem cell-derived cardiomyocytes, freshly dissociated cardiomyocytes or beating 3D-cell clusters. Cardiac safety assessment is a vital part of drug development since late withdrawals of compound candidates, due to heart liability issues such as ventricular arrhythmia, are very
Nanion Introduces NPC-Certified Cell Lines
Munich, Germany, November 08, 2012; Nanion’s automated patch clamp platforms are known for their high cell compatibility, even for primary cells and stem cells. Nanion now introduces “Nanion Approved Cells”, where commercially available cell lines from several providers have been evaluated and certified based on cell and platform performance. The approved cells can be directly purchased through Nanion, so that Nanion’s customers get a complete package of APC platform and
Nanion Acquires the SURFE2R Technology for Transporter Protein Analysis
Nanion acquires the well-established SURFE2R technology, allowing state-of-the-art measurements of transporter protein activity and function. The SURFE2R technology is an excellent enhancement to Nanion’s existing products which until now covered ion channels and nanopores. Nanion Technologies is one of the leading providers of high quality automated patch clamp systems. Nanion’s efficient and versatile products drastically improve the data output in patch clamp-based ion channel screening, safety testing and scientific research. Since

All 5 Releases


More Releases for SyncroPatch

Nanion Starts Shipping the SyncroPatch 384 Patch Engine - a Revolutionary Instru …
The brand-new SyncroPatch 384 Patch Engine (PE) now released by Nanion Technologies propels ion channel drug discovery to a new level. Designed for seamless integration into process-automated drug screening environments, the Patch Engine is equipped with 384 patch clamp amplifiers and an advanced 384 channel liquid handling robot. The SyncroPatch 384PE is the high quality, automated patch clamp system able to finally thrust gold standard electrophysiology from secondary to primary
Nanion Acquires the SURFE2R Technology for Transporter Protein Analysis
Nanion acquires the well-established SURFE2R technology, allowing state-of-the-art measurements of transporter protein activity and function. The SURFE2R technology is an excellent enhancement to Nanion’s existing products which until now covered ion channels and nanopores. Nanion Technologies is one of the leading providers of high quality automated patch clamp systems. Nanion’s efficient and versatile products drastically improve the data output in patch clamp-based ion channel screening, safety testing and scientific research. Since
Nanion Celebrates Its 10th Anniversary - Still With A Strong Focus On New Innova …
Munich, Germany, January 15, 2012; Today, Nanion celebrates 10 years of innovation, scientific product development and successful roll-outs of several product families. Nanion is a success story of organic, revenue-based company growth and dedicated young professionals. 10 years ago, Nanion Technologies started out in a small loft at the Institute of Physiology of Ludwig-Maximilian’s University in Munich. Since then, Nanion has grown from 2 to 40 employees and has successfully
Nanion opens new branch in China
Nanion announces the opening of yet another branch. To meet the needs of the rapidly expanding number of customers in China, the dedicated sales- and support team in Beijing now opens the doors to Nanion Technologies China. Nanion successfully entered the Chinese market over five years ago, and the installed base of Patchliner and Port-a-Patch instruments has grown constantly ever since. To cover the increasing interest and activities within the
Nanion’s automated patch clamp platforms show unparalleled results using stem …
Munich, Germany, September 16, 2011; The Patchliner and the SyncroPatch 96 have successfully been used for compound analysis under current- and voltage clamp recording conditions using different stem cell-derived cardiomyocytes. The exceptional cell-platform-compatibility and the unique experimental possibilities offered by Nanion’s platforms open up whole new avenues for compound safety testing. Pluripotent stem cell-derived cardiomyocytes have tremendous potentials for cardiac safety and efficacy testing of drug candidates. By offering an
Nanion opens US-office in New Jersey
Munich, Germany, February 17th, 2009: Nanion today announces the opening of Nanion Technologies Inc. with headquarters in North Brunswick, NJ, USA. To support the increasing demand of Nanion’s products, and to continue giving premium customer service, Nanion now expands its presence in the American market. Nanion opens the doors to the US-office in the “Heart of Pharma”, North Brunswick, NJ. Nanion Technologies Inc. has a fully equipped demonstration and service